Clinical Trial Search

Primary: Number of Participants With Disease Recurrence At 1 Year — 2; 0 Participants

Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants

Primary: Total Inflammatory Lesion Count — 18.55; 24.51; 20.04 lesions

Primary: Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC) — 9.33; 9.17 months — p=0.6528

Primary: Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC) — 24.0 Percentage of participants — p=< 0.0001

Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]

Primary: Percentage of Participants With Endoscopic Improvement During Induction Period — 18.0 percentage of participants

Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…

Primary: Proportion of Subjects Achieving at Least 2-point Decrease in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline to Week 4 — 35; 37; 29; 36 Participants

Primary: Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux Capacity — -0.013 percentage of cholesterol

Primary: Change in Inferior Corneal Fluorescein Staining Score Post Controlled Adverse Environment (Post-Controlled Adverse Environment (CAE)) — -0.57; -0.44 scores on a scale…

Primary: Overall Survival — 4.8 months

Primary: Changes in Modified Gingival Index (MGI) — 8.5; 1.5 score on a scale — p=<0.001

Primary: Change From Baseline in LDH Level at Week 25 — -683.29 U/L

Primary: The Number of Participants With Treatment Emergent Adverse Events (All TEAEs). — 5; 5; 0 Participants